Patents by Inventor Jasjit S. Bindra

Jasjit S. Bindra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing a lactone
    Patent number: 4122093
    Abstract: A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.
    Type: Grant
    Filed: April 14, 1977
    Date of Patent: October 24, 1978
    Assignee: Pfizer Inc.
    Inventors: Elias J. Corey, Jasjit S. Bindra, Thomas K. Schaaf
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 4113723
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: November 23, 1977
    Date of Patent: September 12, 1978
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 4102894
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 15, 1976
    Date of Patent: July 25, 1978
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Substituted .omega.-pentanorprostaglandins
    Patent number: 4087604
    Abstract: Substituted novel .omega.-pentanorprostaglandins and various novel intermediates and reagents used in their preparation.
    Type: Grant
    Filed: January 3, 1977
    Date of Patent: May 2, 1978
    Assignee: Pfizer Inc.
    Inventors: Jasjit S. Bindra, Michael R. Johnson
  • Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
    Patent number: 4085213
    Abstract: A series of tetrazolo[a]quinazol-5-ones, methods for their production and use as antiallergy agents and antiulcer agents.
    Type: Grant
    Filed: December 23, 1976
    Date of Patent: April 18, 1978
    Assignee: Pfizer Inc.
    Inventor: Jasjit S. Bindra
  • Furyl-2-oxo-alkanephosphonates
    Patent number: 4080368
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: April 21, 1977
    Date of Patent: March 21, 1978
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • N-(5-Tetrazolyl)-4-oxo-4H-pyrimido(2,1-b)benzothiazole-3-carboxamide antiallergy agents
    Patent number: 4041163
    Abstract: N-(5-Tetrazolyl)-4-oxo-4H-pyrimido[2,1-b]benzothiazoles and their use as antiallergy agents.
    Type: Grant
    Filed: March 29, 1976
    Date of Patent: August 9, 1977
    Assignee: Pfizer Inc.
    Inventors: Jasjit S. Bindra, Saul B. Kadin
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 4036832
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 15, 1976
    Date of Patent: July 19, 1977
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanopro staglandins
    Patent number: 4035360
    Abstract: The magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorpr ostaglandins are disclosed. The novel prostaglandin salt of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action and are further valuable because they are crystalline and thus may be easily isolated, purified and compounded into medicaments.
    Type: Grant
    Filed: December 22, 1975
    Date of Patent: July 12, 1977
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Thomas K. Schaaf, Jasjit S. Bindra, Hans-Jurgen E. Hess, James F. Eggler
  • Substituted .omega.-pentanorprostaglandins
    Patent number: 4024179
    Abstract: Substituted novel .omega.-pentanorprostaglandins and various novel intermediates and reagents used in their preparation.
    Type: Grant
    Filed: November 7, 1973
    Date of Patent: May 17, 1977
    Assignee: Pfizer Inc.
    Inventors: Jasjit S. Bindra, Michael R. Johnson
  • 13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins of the two series
    Patent number: 4011262
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: March 8, 1977
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Novel prostaglandin intermediates
    Patent number: 3992438
    Abstract: A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.
    Type: Grant
    Filed: November 19, 1975
    Date of Patent: November 16, 1976
    Assignee: Pfizer Inc.
    Inventors: Elias J. Corey, Jasjit S. Bindra, Thomas K. Schaaf
  • P-biphenyl esters of 15-substituted-.omega.-pentanorprostaglandins
    Patent number: 3984424
    Abstract: The p-biphenyl esters of 15-substituted-.omega.-pentanorprostaglandins are disclosed. The novel prostaglandin esters of the invention exhibit the biological properties of corresponding prostaglandins from which they are derived, but have reduced side effects, and are further valuable because they are easily crystallized and thus may be simply isolated and purified and compounded into medicaments.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: October 5, 1976
    Assignee: Pfizer Inc.
    Inventors: Thomas K. Schaaf, Jasjit S. Bindra, Michael R. Johnson
  • 11-Desoxy-16-aryl-.omega.-tetranorprostaglandins
    Patent number: 3984400
    Abstract: 11-Desoxy-16-aryl-.omega.-tetranorprostaglandins and various intermediates and processes employed in their preparation are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: October 21, 1975
    Date of Patent: October 5, 1976
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Jasjit S. Bindra, Hans-Jurgen E. Hess
  • 15-Substitute D-.omega.-pentanorprostaglandins
    Patent number: 3980642
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: November 19, 1975
    Date of Patent: September 14, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • 13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins
    Patent number: 3974213
    Abstract: The 15 aryl substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: August 10, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • 15-Substituted-.omega.-pentanorprostaglandins
    Patent number: 3971826
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: July 27, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Heterocyclic 15-substituted-.omega.-pentanorprostoglandins
    Patent number: 3956284
    Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: July 3, 1974
    Date of Patent: May 11, 1976
    Assignee: Pfizer Inc.
    Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
  • Prostaglandin intermediates
    Patent number: 3943151
    Abstract: A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.
    Type: Grant
    Filed: October 24, 1973
    Date of Patent: March 9, 1976
    Assignee: Pfizer Inc.
    Inventors: Elias J. Corey, Jasjit S. Bindra, Thomas K. Schaaf
  • 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.ome ga.-pentanorprostaglandins
    Patent number: 3932389
    Abstract: The 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorpr ostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: December 11, 1974
    Date of Patent: January 13, 1976
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Thomas K. Schaaf, Jasjit S. Bindra, Hans-Jurgen E. Hess, James F. Eggler